Information Provided By:
Fly News Breaks for November 16, 2015
AZN, CLVS
Nov 16, 2015 | 10:27 EDT
Goldman Sachs analyst Terence Flynn put his Conviction Buy rating and $123 price target on Clovis Oncology (CLVS) under review following this morning's regulatory update for rociletinib. The news is a "significant setback," especially since the updated response rates are below that of AstraZeneca's (AZN) competitor drug, Flynn tells investors in a research note.
News For CLVS;AZN From the Last 2 Days
AZN
Mar 18, 2024 | 08:17 EDT
Checkpoint Therapeutics (CKPT) announced the appointment of Amit Sharma, M.D., FACP, FASN, FNKF, to its Board as an independent, non-executive director, effective immediately. Dr. Sharma currently serves as Vice President of Clinical Development and Therapeutic Head for Nephrology and Hematology at Alexion, AstraZeneca (AZN) Rare Disease.